Vicuron Pharmaceuticals Inc. filed a new drug application for its lead product, anidulafungin, an antifungal agent for the treatment of esophageal candidiasis, an infection of the esophagus that commonly affects patients with compromised immune systems. (BioWorld Today)

Genzyme General received FDA approval of the orphan drug Fabrazyme, an enzyme replacement therapy for a rare, genetic disorder called Fabry's disease. (BioWorld Today)

Genzyme General received FDA approval of the orphan drug Fabrazyme, an enzyme replacement therapy for a rare, genetic disorder called Fabry's disease. (BioWorld Today)

Taking the opportunity to leverage its commercial expertise with the product TOBI, Chiron Corp. acquired exclusive worldwide development and commercial rights to a product being developed by Novartis AG. (BioWorld Today)